If it hasn't passed FDA muster yet, it is not worth the hype." New products are being tested all the time Peptides may be all the rage, but it takes time to test and bring new products to market
For the full analysis inclusive of demographics, comorbidities, and social drivers of health data for the population, methodology, additional findings, limitations, and citations you can view the complete report on MedRxiv or directly within Truveta Studio
As research progresses, GLP-1 will likely become an integral part of weight loss plans
The influence of gut dysbiosis in the pathogenesis and management of ischemic stroke
Zhu H, Itoh K, Yamamoto M, Zweier JL, Li Y
CONCLUSIONS GLP-1-RAs may provide clinical benefits for patients with IIH, improving outcomes and reducing the need for invasive interventions